Objectives: The pharmacokinetics of lipid-formulated amphotericin B (AMB), and of AMB that has dissociated from its lipid moiety and bound to lipoproteins in plasma, were separately determined in critically ill patients.
Introduction
Systemic fungal infections are a major problem in medical intensive care, because many critically ill patients present with a compromised immunological status, for several reasons. These include liver failure, previous immunosuppressive or antineoplastic chemotherapy, bone marrow or organ transplantation, or acquired immunodeficiency syndrome; longterm broad-spectrum antibiotic treatment may favour fungal overgrowth. 1, 2 Amphotericin B (AMB) is the standard drug for therapy of invasive fungal infections. The targets of its action are the ergosterol components of the fungal cell membrane. Its therapeutic use, however, is limited by significant side effects, such as nephrotoxicity, hepatotoxicity and acute toxicity, including chills and hypotension. [3] [4] [5] [6] Lipid formulations of AMB, liposomal AMB, AMB colloidal dispersion and AMB lipid complex have been developed to overcome these problems. Liposomal AMB comprises spherical liposomes, 45-80 nm in diameter. The liposomal bilayer membrane contains hydrogenated soy phosphatidylcholine, cholesterol, distearoylphosphatidylglycerol and AMB in a molecular ratio of 2:1:0.8: 0.4. 7 AMB colloidal dispersion is a lipid formulation containing AMB as a cholesteryl sulphate complex in a molecular ratio of 1:1, forming disc-like structures ∼74-170 nm in diameter and ∼4 nm thick. 8 Free AMB plasma concentrations are claimed to be very low since free AMB is almost insoluble in water. AMB is bound to plasma proteins, mainly to low-density lipoprotein (LDL), after dissociation from its lipid moiety. 9 Accumulation of lipid-formulated drug at the sites of fungal infection is said to be responsible for its efficacy, in spite of the absence of free AMB in plasma. 8, [10] [11] [12] Several studies on the pharmacokinetics of AMB deoxycholate, liposomal AMB and AMB colloidal dispersion have been performed. [13] [14] [15] [16] [17] [18] Data in patients on haemofiltration, however, are very sparse and only total AMB has been measured so far. [18] [19] [20] Separation of liberated AMB from lipidformulated AMB for differential pharmacokinetics has not been performed.
Since acute renal failure and the need for haemofiltration occur frequently in critically ill patients with multiorgan failure, the influence of continuous veno-venous haemofiltration (CVVH) on the pharmacokinetics of lipid-formulated AMB would have great relevance for appropriate dosage. In this study, the pharmacokinetics of lipoprotein-bound and lipidformulated AMB were separately determined in critically ill patients. Elimination of lipid-formulated and lipoproteinbound AMB by haemofiltration was studied.
Patients and methods

Patients
The study was performed between October 1999 and March 2001. A total of 16 consecutive critically ill patients requiring AMB treatment for proposed or proven invasive fungal infection were included. 21 Informed consent was obtained when possible, or patients were informed about the scientific use of their clinical data after waking from analgesia/sedation. The study was performed according to the guidelines of the local ethics committee and to Austrian law. The main characteristics of the patients, their treatments and the number of assays performed in each patient are listed in Table 1 .
Lipid-formulated AMB was used in patients with impaired renal function or concomitant nephrotoxic medication. Patients who were included before 1 July 2000 received liposomal AMB; from 1 July 2000, AMB colloidal dispersion was used. In patients already administered lipid-formulated AMB (liposomal AMB or AMB colloidal dispersion) at the time of admission, the respective therapy was continued.
Four patients received AMB deoxycholate (patients 1-4). Two of them were undergoing haemofiltration for irreversible, terminal renal failure (patients 1 and 2). Seven patients were treated with liposomal AMB (patients 1 and 5-10), five of whom were receiving CVVH (patients 1 and 5-8), whereas three were not (patients 5, 9 and 10). Eight patients were undergoing therapy with AMB colloidal dispersion (patients 2, 7 and 11-16), seven required CVVH (patients 2, 7 and 11-15), three did not (patients 14-16; see Table 1 ). Thus six patients were allocated to more than one group: patients 1 and 2 were changed from liposomal AMB to AMB deoxycholate therapy. Patient 7 had to be moved from AMB colloidal dispersion to liposomal AMB because of acute toxicity. Patients 5, 14 and 15 were weaned from haemofiltration because their renal function had recovered (see Table 1 ).
Drug administration and preparation
AMB deoxycholate (Bristol-Myers-Squibb, Vienna, Austria), liposomal AMB (AmBisome NeXstar Pharmaceuticals, Boulder, CO, USA) and AMB colloidal dispersion (Amphocil, Sequus Pharmaceuticals Inc., Menlo Park, CA, USA) were dissolved, as recommended by the manufacturer, and diluted in 500 mL of 5% dextrose. The infusion time was 4 h for AMB deoxycholate, liposomal AMB and AMB colloidal dispersion. The dosages are shown in Table 3 . All assays were performed under steady-state conditions (after a mean AMB treatment duration of 7.78 days). The replacement fluid was administered in the pre-dilution mode. Interruption of the haemofiltration process occurred during some of the sampling periods due to clotting of the filter or diagnostic procedures, such as computer-assisted tomography. Details of the haemofiltration protocols are described in Table 2 .
Haemofiltration
Measurement of lipoprotein-bound and lipid-formulated AMB by HPLC
Arterial blood samples of 2 mL were drawn into heparinized vials (Monovette, Sarstedt, Nümbrecht, Germany) before, as well as 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 h after the start of the respective infusion. In one experiment (patient 2, experi- ment 2), venous blood samples were also drawn, to provide a comparison between arterial and venous plasma concentrations of AMB. Samples were centrifuged immediately (10 min, 2000 rpm), and plasma was frozen and stored at -75°C. Plasma levels of lipoprotein-bound and lipid-formulated AMB were separated using Bond Elut C 18 (100 mg) solidphase extraction cartridges (Varian, Palo Alto, CA, USA). The lipid-formulated substance was not retained on the cartridge, whereas plasma-lipoprotein-bound AMB as well as AMB deoxycholate was retained and eluted off the column with 60% acetonitrile in water, as described previously. 22 HPLC analysis was performed with a Lichrosorb RP-8 column (200 × 4.6 mm; 5 µm; Agilent Technologies, Palo Alto, CA, USA) connected to a Zorbax SB-C 8 precolumn (12.5 × 4.6 mm; 5 µm; Agilent Technologies). AMB was measured by a UV detector at 405 nm. The detection limit was 0.005 µg/mL. 22 Total AMB plasma concentrations were obtained by the addition of concentrations of lipoprotein-bound and lipid-formulated AMB. Pharmacokinetic parameters for total AMB were derived from these calculated data.
Pharmacokinetic calculations and statistical evaluation
Pharmacokinetics were calculated using a non-compartmental model. The calculations were performed with the Kinetica 2000 program (InnaPhase Corporation, Champs-sur-Marne, France). The area under the concentration-time curve from time zero to time n of the last sample (AUC 0-n ) was computed using the log linear method, whenever the concentration in a trapezoid decreased, or the trapezoidal method was applied when the concentration increased (C n > C n-1 ). AUC 0-n is defined as AUC 0-n from t = 0 to t last = 24 h, AUC 0-n is AUC 0-24 . The statistical significance of the results was evaluated by the Mann-Whitney U-test.
AMB concentrations in ultrafiltrate and urine
Ultrafiltrate samples were drawn from the ultrafiltrate outlet of the haemofilter. Concentrations of free and lipid-formulated AMB were determined as described. 22 Calculation of haemofilter clearance was performed using the formula: Urine samples were drawn from a urinary catheter. Renal clearance of liberated, lipid-formulated and total AMB was determined in one patient treated with liposomal AMB, who was receiving CVVH (patient 5), but had residual diuresis of 1200 mL per day, and in two patients treated with AMB colloidal dispersion (patient 15 during CVVH and patient 14 after recovery of renal function and weaning from haemofiltration). In patient 5, 11 urine samples and 11 plasma samples were drawn on two different days, in patient 15, eight urine and eight plasma samples on two days. In patient 14, 12 urine and 12 plasma samples were analysed. Renal clearance was calculated using the formula:
Extraction of AMB from haemofilters
AMB adsorption to haemofilters was analysed in three patients (patient 3, who had received liposomal AMB 300 mg, patient 5, liposomal AMB 200 mg and patient 10, AMB colloidal dispersion 100 mg). After the monitoring period, the plastic casings of the used haemofilters were opened and the polysulphone hollow fibres cut into small pieces ∼1 mm long, and suspended in water. Total AMB was extracted with acetonitrile (Merck) by shaking and incubation at 37°C overnight. Acetonitrile was removed with an evaporator at 60°C, and the pellets were resuspended in water. After purification by Bond ElutC 18 cartridges, total AMB was measured by HPLC as described. 22
Results
Plasma pharmacokinetics of AMB during therapy with AMB deoxycholate, liposomal AMB and AMB colloidal dispersion
The time-concentration profiles of lipoprotein-bound and lipid-formulated AMB for patients treated with AMB deoxycholate, liposomal AMB and AMB colloidal dispersion on and off haemofiltration are displayed in Figure 1 . Table 3 shows the main pharmacokinetic parameters for lipoproteinbound AMB for patients on therapy with AMB deoxycholate, as well as for lipoprotein-bound, lipid-formulated and total AMB during treatment with liposomal AMB and AMB colloidal dispersion. C max and AUC 0-24 of total and lipidformulated AMB were significantly higher in patients on haemofiltration treated with liposomal AMB than in patients treated with AMB colloidal dispersion (P = 0.0045 for C max and for AUC 0-24 for lipid-formulated and for total AMB). During CVVH, clearance (CL) and V d of total and lipidformulated AMB were significantly lower in patients on liposomal AMB than in those on AMB colloidal dispersion (lipid-formulated AMB: P = 0.0045 for CL, P = 0.0074 for V d , total AMB: P = 0.0185 for CL, P = 0.0118 for V d ). A significant difference between the haemofiltration group and the control group was only observed for the clearance of lipidformulated and total AMB during therapy with liposomal AMB; it was higher in the haemofiltration group (0.198 L/h/kg versus 0.079 L/h/kg, P = 0.0253 and 0.140 L/h/kg versus 0.061 L/h/kg, P = 0.0369, respectively, see Table 3 ).
However, several minor, non-significant differences in pharmacokinetic parameters were detected. During treatment with AMB deoxycholate and AMB colloidal dispersion, C max and AUC 0-24 of protein-bound AMB were lower in patients on haemofiltration than in those who were not. C max and AUC 0-24 of liposomal AMB were also slightly lower in the CVVH group than in the control group. For AMB colloidal dispersion the opposite was the case (see Table 3 and Figure 1) .
The half-life of protein-bound AMB during AMB deoxycholate treatment was shorter when CVVH was performed. In patients treated with liposomal AMB, however, it appeared to be longer in the haemofiltration group; for AMB colloidal dispersion treatment, no difference in t 1/2 of protein-bound AMB was found between the haemofiltration and control groups. The half-life of liposomal AMB was unchanged by CVVH, whereas that of AMB colloidal dispersion was enhanced in the CVVH group (see Table 3 ).
The clearance and volume of distribution of protein-bound as well as of lipid-formulated AMB were enhanced in the haemofiltration group, but the difference was significant only for liposomal AMB (lipid-formulated fraction), as mentioned above. For clearance of AMB colloidal dispersion (lipidformulated fraction), no influence of haemofiltration was found (see Table 3 ).
No correlation between variables of the haemofiltration process, interruptions, running time ('age') of the haemofilter, ultrafiltration rate or blood flow was found by linear regression.
In one patient, who was treated with AMB deoxycholate, arterial and venous AMB plasma concentrations were determined. The venous AMB concentration was slightly higher (by 6.9% on average). The difference was most pronounced during the infusion of the drug.
AMB concentrations in ultrafiltrate, sieving coefficient and haemofilter clearance
AMB concentrations in the ultrafiltrate of patient 1 were measured during treatment with AMB deoxycholate. The maximum AMB level in ultrafiltrate was observed at the end of infusion and accounted for 0.23 µg/mL; C max in plasma was 0.76 µg/mL. The sieving coefficient for AMB was 0.29, the haemofilter clearance (CL HF ) 0.42 L/h (8.10% of total CL).
Liberated AMB and liposomal AMB were measured in the ultrafiltrates of three patients on therapy with liposomal AMB. The peak concentration of free AMB appeared in ultrafiltrate 3-4 h after the start of the infusion of liposomal AMB, and accounted for 0.079 µg/mL ± 0.039 (mean + S.D.). The mean plasma peak concentration in the same three patients was 1.52 µg/mL. Small amounts of free AMB could be detected in all ultrafiltrate samples. The mean sieving coefficient for free AMB was 0.16 during therapy with liposomal AMB. Liposomal AMB was not detected in the majority of ultrafiltrate samples; only at the end of infusion (3-4 h after the start) could small amounts (mean C maxUF 0.065 µg/mL) be found. The sieving coefficient for liposomal AMB was below 0.04, and the clearance of liposomal AMB by haemofiltration was as low as 0.06 L/h (0.40% of the total body clearance of liposomal AMB). In the ultrafiltrate of patients treated with AMB colloidal dispersion, the mean peak concentration of free AMB was 0.095 µg/mL (+0.012). The average clearance of free AMB by haemofiltration was 0.25 L/h during therapy with AMB colloidal dispersion (2.20% of total clearance). Only in a few ultrafiltrate samples was AMB colloidal dispersion (lipidformulated form) detected (0.201 µg/mL, 1.5 h after start of infusion). The sieving coefficient of AMB colloidal dispersion was 0.07 and the haemofilter clearance 0.20 L/h (0.03% of the total clearance of AMB colloidal dispersion). The sieving coefficient of total AMB (AMB colloidal dispersion and free AMB) was 0.29, the haemofilter clearance 0.142 L/h (2.30% of total body clearance).
AMB recovered from haemofilter
Adsorption of AMB to haemofilters was analysed in three used haemofilters. Two had been run in patients treated with liposomal AMB, one was taken from a patient who had received AMB colloidal dispersion. AMB was recovered from all haemofilters. A total of 0.53 µg and 0.39 µg of AMB was recovered from the haemofilters of patients treated with liposomal AMB, and 0.16 µg from the haemofilter run in the patient treated with AMB colloidal dispersion.
Renal AMB clearance
Renal clearance of liposomal AMB was measured in a patient who was undergoing haemofiltration, but had a residual diuresis of 1200 mL per day (patient 5). In this patient, the mean renal clearance of free AMB was 0.133 L/h (0.97% of total clearance), renal clearance of lipid-formulated 0.014 L/h (0.15% of total body clearance) and that of total AMB was 0.052 L/h (0.86% of total body clearance). In patient 15, who was on haemofiltration, after administration of AMB colloidal dispersion, mean renal clearance of free AMB accounted for 0.294 L/h (1.10% of total clearance of free AMB), clearance of lipid-formulated 0.173 L/h (0.96% of total clearance) and that of total AMB 0.363 L/h (1.70% of total clearance). In patient 14, who had obtained AMB colloidal dispersion and had approximately normal renal function, renal clearance of free AMB was as low as 0.004 L/h (0.04% of total clearance), whereas no renal clearance of lipid-formulated AMB could be identified (urine levels were below the detection limit).
Discussion
Several studies on the pharmacokinetics of liposomal AMB and AMB colloidal dispersion have been performed in animal models as well as in humans. 8, 11, 15, 16, 18, 23 In all these studies only total AMB plasma concentrations have been measured, without distinguishing lipid-formulated AMB from AMB that has dissociated from its lipid moiety. The latter is insoluble in water and therefore bound to lipoproteins in plasma. 9 In this study, we applied a new chromatographic technique developed for separate measurement of lipid-formulated and lipoprotein-bound drug levels. 22 In this way, we compared the pharmacokinetic behaviour of two different lipid formulations, liposomal AMB and AMB colloidal dispersion, in critically ill patients, and evaluated the effects of haemofiltration.
Plasma pharmacokinetics of AMB deoxycholate have been studied by other investigators. 13, 24 Because of its nephrotoxicity, this substance is not usually administered to patients with renal failure treated with haemofiltration. In terminal renal failure, however, when recovery of renal function cannot be expected, therapy with AMB deoxycholate is possible. AMB plasma levels during treatment with AMB deoxycholate were measured in two critically ill patients with normal renal function and in two patients with terminal renal failure, who were on CVVH. A high variability of AMB pharmacokinetics is known. 13 Pharmacokinetic data derived from our two patients not undergoing haemofiltration are in agreement with the literature. 8, 18 No pharmacokinetic data for patients receiving haemofiltration have been published, to our knowledge. In our two patients undergoing CVVH, we observed a slightly enhanced AMB clearance and a higher volume of distribution, whereas peak concentrations and AUC 0-24 were somewhat lower in comparison with patients not receiving CVVH. A slightly enhanced elimination of AMB may be considered in patients administered haemofiltration.
Up to now, the pharmacokinetics of liposomal AMB have been studied in only one patient undergoing haemofiltration 18 and in another, haemodiafiltration. 20 Peak and trough levels were measured in one additional patient treated with CVVH. 19 No effect of haemofiltration on the pharmacokinetics of total AMB levels was found in these patients. The pharmacokinetics of AMB colloidal dispersion have been investigated only in healthy volunteers. 15, 16 In the present study, total AMB levels have been calculated by adding lipoprotein-bound and lipid-formulated AMB, for comparison with existing data. While volume of distribution and clearance observed in our critically ill patients are in good agreement with previously published data, the half-life and AUC 0-24 were much lower in critically ill patients (21 versus 235 h and 9.59 versus 56.8 mg⋅h/L).
In patients treated with liposomal AMB, C max and AUC 0-24 of total and lipid-formulated AMB were significantly higher than in those who had received AMB colloidal dispersion at comparable doses, whereas CL and V d were significantly lower. This difference was observed in patients treated with CVVH as well as those not undergoing haemofiltration. In patients not receiving haemofiltration, different elimination rates of total AMB from plasma have been described, and explained as resulting from rapid particle uptake of AMB colloidal dispersion by the reticulo-endothelial system, while the smaller particles of liposomal AMB remain in the circulation for longer. 11, 12 When the pharmacokinetics of liberated lipoprotein-bound AMB were compared, however, no significant difference between liposomal AMB and AMB colloidal dispersion was noted. There was a tendency for lower plasma levels during haemofiltration in the group treated with AMB colloidal dispersion (C max of lipoproteinbound AMB was 0.4 µg/mL versus 0.6, and AUC 0-24 was 3.61 versus 8.54 mg⋅h/L, not significant), which may also, in part, be related to the fact that doses administered were not identical. The enhanced volume of distribution, however, which was found during haemofiltration, may be the most probable explanation of the increased removal of AMB from plasma.
Beside elimination by ultrafiltration, adsorption to the haemofilter membrane may influence the pharmacokinetics of drugs during CVVH. 25, 26 This phenomenon is difficult to assess, since it depends on the physicochemical properties of the haemofilter membrane and several other variables of the haemofiltration process, such as ultrafiltration rate and blood flow through the haemofilter. We addressed this problem by dissecting three haemofilters after usage and estimating the amount of AMB recovered. Relatively low amounts of the drug were recovered, and no excessive adsorption to the haemofilter has to be expected.
The clearance of lipoprotein-bound AMB by ultrafiltration contributed to the total clearance to a low extent (∼2%); for lipid-formulated AMB there was almost no clearance by ultrafiltration. The sieving coefficient and the renal clearance of lipid-formulated AMB were low.
The main advantage of lipid-formulated AMB is the increased therapeutic index achieved by reduced toxicity. Compared with liposomal AMB, AMB colloidal dispersion has a higher acute toxicity. [27] [28] [29] This was also observed in our study (patient 7 had to be moved from AMB colloidal dispersion to liposomal AMB because of infusion-related chills and fever). The difference in toxicity has been thought to be due to the lower plasma levels of 'free' AMB with liposomal AMB, when compared with AMB colloidal dispersion. 12 Since we found similar plasma concentrations of liberated lipoproteinbound AMB in patients treated with the two lipid formulations, our data do not support this hypothesis.
Whereas the pharmacokinetics of AMB liberated from the lipid moiety are similar to those of AMB deoxycholate, the pharmacokinetics of lipid-formulated AMB are different. Furthermore, the pharmacokinetic parameters of liposomal AMB differ from those of AMB colloidal dispersion: clearance and volume of distribution of AMB colloidal dispersion exceed those of liposomal AMB by >10-and 50-fold, respectively. In critically ill patients, the pharmacokinetics of liberated AMB are similar, whether undergoing haemofiltration or not. The significant influence of haemofiltration on AMB elimination was observed only for liposomal AMB, where the clearance was enhanced by a factor of two. Clearance of AMB colloidal dispersion also appeared to be increased during haemofiltration, but this difference was not significant. Thus pharmacokinetics of lipoprotein-bound and lipidbound AMB are different and differentially influenced by CVVH.
Since the amount of AMB that has dissociated from its lipid moiety during treatment with lipid-formulated AMB has not been investigated in critically ill patients so far, its relevance for fungicidal efficacy of the drug is not clear. A mechanism without dissociation of AMB from the lipid moiety in the circulation has been suggested. Phospholipases are hypothesized to be involved in the liberation of AMB from its lipid moiety at the target site. 10, 12 In the light of our observations, a model covering the activity of 'free' AMB is attractive. A head-to-head study comparing the clinical efficacy of liposomal AMB and AMB colloidal dispersion is still lacking. Nevertheless, clinical studies on liposomal AMB and on AMB colloidal dispersion have confirmed a comparable clinical efficacy for both preparations. 9,30-39 This provides additional indirect evidence of the impact of dissociation of AMB from the lipid moiety, since plasma levels are similar only for the liberated, lipoprotein-bound fraction.
In this study of consecutive cases, patient sample discrepancies are likely to reflect variations in the actual patient population of intensive care units. For a more detailed pharmacokinetic study, a standardized protocol with inclusion and exclusion criteria and a standardized haemofiltration procedure would be required.
In conclusion, in critically ill patients with renal failure treated with CVVH, AMB does not accumulate when liposomal AMB or AMB colloidal dispersion is administered at the standard dose. Elimination even seems to be slightly enhanced, especially that of liposomal AMB. Based on the pharmacokinetics of the active moiety of the preparations, 'free' AMB, which is lipoprotein-bound in the plasma, no superiority of either of the two lipid formulations (liposomal AMB or AMB colloidal dispersion) has been shown in the treatment of critically ill patients on CVVH, and administration of the standard dose of 3-4 mg/kg can be recommended for this group of patients.
